Wei Wang1, Guang-Xu Liu2, Yue-Hua Li1, Xue-Dong Li1, Yan He2. 1. Department of Ophthalmology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. 2. Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing 100069, China.
Abstract
AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro. METHODS: The effects of TNMD and ranibizumab on VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) were evaluated by MTT assay, and the effects of TNMD and ranibizumab on capillary-like structures formed by HUVECs under the stimulation of VEGF were examined in culture. Capillary-like morphogenesis of HUVECs was quantitatively evaluated, and total lengths of tube-like structures per field were measured in a masked way. RESULTS: HUVECs with both ranibizumab and TNMD protein showed MTT reduction in VEGF-stimulated cell proliferation as expected, while MTT absorbance in the HUVECs with TNMD was significantly declined than that with ranibizumab (P<0.01). The capillary-like structures formed by HUVECs were markedly impaired by the presence of both TNMD and ranibizumab in the culture medium. The total length of the capillary-like structures per field was significantly shorter in the medium with TNMD than that of ranibizumab (P<0.01). The inhibitory effect of TNMD on tube formation in vitro angiogenesis was significantly stronger than that of ranibizumab. CONCLUSION: TNMD may have stronger inhibitory effect than ranibizumab on in vitro angiogenesis.
AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro. METHODS: The effects of TNMD and ranibizumab on VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) were evaluated by MTT assay, and the effects of TNMD and ranibizumab on capillary-like structures formed by HUVECs under the stimulation of VEGF were examined in culture. Capillary-like morphogenesis of HUVECs was quantitatively evaluated, and total lengths of tube-like structures per field were measured in a masked way. RESULTS: HUVECs with both ranibizumab and TNMD protein showed MTT reduction in VEGF-stimulated cell proliferation as expected, while MTT absorbance in the HUVECs with TNMD was significantly declined than that with ranibizumab (P<0.01). The capillary-like structures formed by HUVECs were markedly impaired by the presence of both TNMD and ranibizumab in the culture medium. The total length of the capillary-like structures per field was significantly shorter in the medium with TNMD than that of ranibizumab (P<0.01). The inhibitory effect of TNMD on tube formation in vitro angiogenesis was significantly stronger than that of ranibizumab. CONCLUSION:TNMD may have stronger inhibitory effect than ranibizumab on in vitro angiogenesis.
Authors: Atsuhito Saiki; Maja Olsson; Margareta Jernås; Anders Gummesson; Philip G McTernan; Johanna Andersson; Peter Jacobson; Kajsa Sjöholm; Bob Olsson; Shigeo Yamamura; Andrew Walley; Philippe Froguel; Björn Carlsson; Lars Sjöström; Per-Arne Svensson; Lena M S Carlsson Journal: J Clin Endocrinol Metab Date: 2009-07-14 Impact factor: 5.958
Authors: Y Zhai; J Ni; G W Jiang; J Lu; L Xing; C Lincoln; K C Carter; F Janat; D Kozak; S Xu; L Rojas; B B Aggarwal; S Ruben; L Y Li; R Gentz; G L Yu Journal: FASEB J Date: 1999-01 Impact factor: 5.191